CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary - Thomson StreetEvents

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary - Thomson StreetEvents
CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary
Published Oct 12, 2021
12 pages (5981 words) — Published Oct 12, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

  
Brief Excerpt:

...Co. announced that it shift focus of COVID-19 vaccine development to second-generation mRNA technology....

  
Report Type:

Brief

Source:
Company:
CureVac NV
Ticker
CVAC.OQ
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

CureVac NV Q4 2021 Earnings Call Summary – 2022-04-28 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q4 2021 Earnings Call Transcript – 2022-04-28 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 28-Apr-22 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Summary – 2021-11-19 – US$ 54.00 – Edited Brief of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV Q3 2021 Earnings Call Transcript – 2021-11-19 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 19-Nov-21 1:00pm GMT

CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript – 2021-10-12 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 12-Oct-21 1:00pm GMT

CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript – 2021-07-01 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 1-Jul-21 12:00pm GMT

CureVac NV Updates On Clinical Trial - Corporate Call Transcript – 2021-06-17 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 17-Jun-21 12:00pm GMT

CureVac NV Q4 2020 Earnings Call Transcript – 2021-04-15 – US$ 54.00 – Edited Transcript of CVAC.OQ earnings conference call or presentation 15-Apr-21 2:00pm GMT

CureVac N.V. - Special Call Transcript – 2021-02-05 – US$ 54.00 – Edited Transcript of CVAC.OQ conference call or presentation 5-Feb-21 3:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary" Oct 12, 2021. Alacra Store. May 02, 2024. <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-To-Discuss-the-Shift-Focus-of-COVID-19-Vaccine-Development-to-Second-Generation-mRNA-Technology-Call-B15005592>
  
APA:
Thomson StreetEvents. (2021). CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Summary Oct 12, 2021. New York, NY: Alacra Store. Retrieved May 02, 2024 from <http://www.alacrastore.com/thomson-streetevents-transcripts/CureVac-NV-To-Discuss-the-Shift-Focus-of-COVID-19-Vaccine-Development-to-Second-Generation-mRNA-Technology-Call-B15005592>
  
US$ 54.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.